Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo

Molecular Therapy

Volumn 16, Issue 1, 2008, Pages 146-153

  Altomonte, Jennifer ^a   Wu, Lan ^a   Chen, Li ^a   Meseck, Marcia ^a   Ebert, Oliver ^a   García Sastre, Adolfo ^a   Fallon, John ^a   Woo, Savio L C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS NDV FUSION PROTEIN; ONCOLYTIC VESICULAR STOMATITIS VIRUS THROMBOSPONDIN FUSION PROTEIN; ONCOLYTIC VIRUS; SIALOGANGLIOTETRAOSYLCERAMIDE ANTIBODY; UNCLASSIFIED DRUG; VIROTHERAPY AGENT; VIRUS FUSION PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; EQUINE HERPES VIRUS; EXPRESSION VECTOR; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IN VIVO STUDY; LIVER CELL CARCINOMA; LYMPHOCYTE DEPLETION; MALE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; RAT; TOXICITY TESTING; TUMOR NECROSIS; VIRUS VIRULENCE;

ANIMALIA; EQUID HERPESVIRUS 1; HUMAN HERPESVIRUS 1; RATTUS; VESICULAR STOMATITIS VIRUS;

EID: 37549027165     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300343     Document Type: Article

References (43)

1. Kim, D, Martuza, RL and Zwiebel, J (2001). Replication-selective virotherapy for cancer: Biological principles, risk management, and future directions. Nat Med 7: 781-787.
2. Coffey, MC, Strong, JE, Forsyth, PA and Lee, PW (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334.
3. Lorence, RM, Katubig, BB, Reichard, KW, Reyes, HM, Phuangsab, A, Sassetti, MD et al. (1994). Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 54: 6017-6021.
4. Peng, KW, Ahmann, GJ, Pham, L, Greipp, PR, Cattaneo, R and Russell, SJ (2001). Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98: 2002-2007.
5. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6 821-825.
6. Letchworth, GJ, Rodriguez, LL and Del cbarrera, J (1999). Vesicular stomatitis. Vet J 157: 239-260.
7. Rose, JK and Whitt, MA (2001). Rhabdoviridae: The viruses and their replication. In: Knipe, DM and Hawley, PM (ed.) Fields Virology, 4th edn, Lippincott Williams & Wilkins: Philidelphia. pp. 1221-1242.
8. Parkin, DM, Sthemswärd, J and Muir, CS (1984). Estimates of the worldwide frequency of twelve major cancers. Bull World Health Organ 62: 163-182.
9. Murray, CJ and Lopez, AD (1996). Evidence-based health policy - lessons from the Global Burden of Disease Study. Science 274: 740-743.
10. Parkin, DM, Bray, F, Ferlay, J and Pisani, P (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156.
11. El-Serag, HB and Mason, AC (1999). Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750.
12. Dyer, Z, Peltekian, K and van Zanten, SV (2005). Review article: The changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther 22: 17-22.
13. Ebert, O, Shinozaki, K, Huang, TG, Savontaus, MJ, Garcia-Sastre, A, and Woo, SL (2003). Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res 63: 3605-3611.
14. Shinozaki, K, Ebert, O, Kournioti, C, Tai, YS and Woo, SL (2004). Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther 9: 368-376.
15. Ebert, O, Shinozaki, K, Koumioti, C, Park MS, García-Sastre, A and Woo, SL (2004). Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 64: 3265-3270.
16. Guidotti, LG and Chisari, FV (2001). Noncytolytic control of viral infections by the innate and adaptive immune response. Ann Rev Immunol 19: 65-91.
17. Schall, TJ and Bacon, KB (1994). Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 6: 865-873.
18. Rollins, BJ (1997). Chemokines. Blood 90: 909-928.
19. Baggiolini, M (1998). Chemokines and leukocyte traffic. Nature 392: 565-568.
20. Alcami, A (2003). Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 3: 36-50.
21. Seet, B and McFadden, G (2002). Viral chemokine-binding proteins. J Leukoc Biol 72: 24-34.
22. Bryant, NA, Davis-Poynter, N, Vanderplasschen, AI and Alcami, A (2003). Glycoprotein G isoforms from some alphaherpesviruses function as broad-spectrum chemokine binding proteins. EMBO J 22: 833-846.
23. Lawson, ND, Stillman, EA, Whitt, MA and Rose, JK (1995). Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92: 4477-4481.
24. Whelan, SP, Ball, LA, Barr, JN and Wertz, GT (1995). Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci USA 92: 8388-8392.
25. Shinozaki, K, Ebert, O, Suriawinata, A, Thung, SN and Woo, S (2005). Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats. J Virol 79 13705-13713.
26. Shinozaki, K, Ebert, O and Woo, SL (2005). Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 41: 196-203.
27. Trinchieri, G (1989). Biology of natural killer cells. Adv Immunol 47: 187-376.
28. Welsh, RM (1986). Regulation of virus infections by natural killer cells. Nat Immun Cell Growth Regul 5: 169-199.
29. Brutkiewicz, RR and Welsh, RM (1995). Major histocompatibility complex class I antigens and the control of viral infections by natural killer cells. J Virol 69: 3967-3971.
30. Baraz, L, Khazanov, E, Condiotti, R, Kotler, M and Nagler, A (1999). Natural killer (NK) cells prevent virus production in cell culture. Bone Marrow Transplant 24: 179-189.
31. Biron, CA, Nguyen, KB, Pien, GC, Cousens, LP and Salazar-Mather, TP (1999). Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu Rev Immunol 17: 189-220.
32. Orange, JS, Fassett, MS, Koopman, LA Boyson, JE and Strominger, JL (2002). Viral evasion of natural killer cells. Nat Immunol 3 1006-1012.
33. Biron, CA and Brossay, L (2001). NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 13: 458-464.
34. Eberl, G, Lees, R, Smiley, ST, Taniguchi, M, Grusby, MJ and MacDonald, HR (1999). Tissue-specific segregation of CD1d-dependent and CDId-independent NK T cells. J Immunol 162: 6410-6419.
35. Mistry, AR and O'Callaghan, CA (2007). Regulation of ligands for the activating receptor NKG2D. Immunology 121: 439-447.
36. Nair, DT, Kaur, KJ, Singh, K, Mukherjee, P, Rajagopal, D, George, A et al. (2003). Mimicry of native peptide antigens by the corresponding retro-inverso analogs is dependent on their intrinsic structure and interaction propensities. J Immunol 170: 1362-1373.
37. Lund, JM, Alexopoulou, L, Sato, A, Karow, M, Adams, NC, Gale, NW et al. (2004). Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 101: 5598-5603.
38. Todo, T, Martuza, RL, Rabkin, SD and Johnson, PA (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98: 6396-6401.
39. Thomas, DL and Fraser, NW (2003). HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Mol Ther 8: 543-551.
40. Benencia, F, Courreges, MC, Conejo-García JR, Buckanovich, RJ, Zhang, L, Carroll, RH et al. (2005). Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum Gene Ther 16 765-778.
41. Yeung, YP, Lo, CM, Liu, CL, Wong, BC, Fan, ST and Wong, J (2005). Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 100: 1995-2004.
42. Wakimoto, H, Johnson, PR, Knipe, DM and Chiocca, EA (2003). Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther 10: 983-990.
43. Wakimoto, H, Fulci, G, Tuminiski, E and Chiocca, EA (2004). Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther 11 214-223.